The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...
The McKenzie Method is recognised globally as an effective approach for treating back pain and training to be qualified in ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
In an international effort, researchers at Western, the University of Maryland School of Dentistry (UMSOD) and Neuroscience ...
Opens in a new tab or window NSAIDs, ketamine, and mid- to high-potency opioids reduced acute pediatric pain, but effects were ... or were supported by low- or very low-certainty evidence, Olejnik ...
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
When to Seek Medical Help Dr. Nicholas Franco urges women experiencing sudden, severe, or persistent pelvic pain to seek medical attention without delay.“Ignoring pelvic pain can lead to serious ...